Entrar Registro gratuito

Beam Therapeutics Ret. em ativos

Qual é o Ret. em ativos de Beam Therapeutics?

O Ret. em ativos de Beam Therapeutics Inc. é -10.65%

Qual é a definição de Ret. em ativos?



Retorno sobre os ativos indica como os ativos de uma empresa são lucrativos na geração de receita. É calculado dividindo-se o lucro líquido pelo total de ativos médios.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Ret. em ativos de empresas na Setor Health Care em NASDAQ em comparação com Beam Therapeutics

O que Beam Therapeutics faz?

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Empresas com ret. em ativos semelhantes a Beam Therapeutics